Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 18:28:e01510.
doi: 10.1016/j.idcr.2022.e01510. eCollection 2022.

Outcomes of caspofungin use in the treatment of Candida-related urinary tract infections, a case series

Laila Rkieh  1 , Wasim S El Nekidy  2   3 , Leen Oyoun Alsoud  2 , Adnan Alatoom  2   4 , Rania El Lababidi  2 , Mohamad Mooty  2 , Ahmad R Nusair  5
Affiliations
Case Reports

Outcomes of caspofungin use in the treatment of Candida-related urinary tract infections, a case series

Laila Rkieh et al. IDCases. .

Abstract

Echinocandins are generally excluded in the treatment of Candida-related urinary tract infections due to their poor urinary concentration. In the presence of fluconazole resistant Candida species, such as C. Glabrata and C. auris, alternative therapies are needed. We herein report the use of caspofungin for the treatment of 10 patients with candiduria, including C. auris. Mycological cure was achieved in 6 of 7 patients and clinical cure was achieved in 8 of 10 patients. Larger studies are needed to confirm our findings.

Keywords: Candiduria; Caspofungin; Urinary tract infection.

PubMed Disclaimer

Conflict of interest statement

All authors declare no potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Similar articles

See all similar articles

Cited by

References

    1. Fisher J.F., Sobel J.D., Kauffman C.A., Newman C.A. Candida urinary tract infections–treatment. Clin Infect Dis. 2011;52(Suppl. 6):S457–S466. doi: 10.1093/cid/cir112. [PMID: 21498839] - DOI - PubMed
    1. Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L., et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi: 10.1093/cid/civ933. [Epub 2015 Dec 16. PMID: 26679628; PMCID: PMC4725385] - DOI - PMC - PubMed
    1. Sobel J.D., Bradshaw S.K., Lipka C.J., Kartsonis N.A. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis. 2007;44(5):e46–e49. doi: 10.1086/510432. [Epub 2007 Jan 22. PMID: 17278048] - DOI - PubMed
    1. Alfouzan W.A., Dhar R. Candiduria: evidence-based approach to management, are we there yet? J Mycol Med. 2017;27(3):293–302. doi: 10.1016/j.mycmed.2017.04.005. [Epub 2017 May 10. PMID: 28501465] - DOI - PubMed
    1. Gajdács M., Dóczi I., Ábrók M., Lázár A., Burián K. Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients: results from a 10-year retrospective survey. Cent Eur J Urol. 2019;72(2):209–214. doi: 10.5173/ceju.2019.1909. [Epub 2019 Jun 29. PMID: 31482032; PMCID: PMC6715075] - DOI - PMC - PubMed

Publication types

LinkOut - more resources